コンテンツへスキップ
Merck

UHPLC (Isocratic) Analysis of 14 Cannabinoids on Ascentis® Express C18

UHPLC (Isocratic) Analysis of 14 Cannabinoids on Ascentis® Express C18 application for UHPLC

材料

分析カラム

製品番号
詳細
価格

Ascentis® Express C18, 2.7 µm HPLCカラム

2.7 μm particle size, L × I.D. 15 cm × 2.1 mm

CONDITIONS

column

Ascentis Express C18, 15 cm x 2.1 mm, 2.7 μm particles (53825-U)

mobile phase

[A] 0.1% formic acid in HPLC water; [B] 0.1% formic acid in acetonitrile; (30:70, A:B)

flow rate

0.6 mL/min

pressure

6390 psi (440 bar)

column temp.

20 °C

detector

UV, 230 nm

injection

2 μL

sample

25 μg/mL each compound in acetonitrile

詳細

アナリシスノート

Cannabinoids are a group of active compounds found in cannabis. They reportedly provide relief to an assortment of symptoms in the treatment of pain, nausea, anxiety, mood disorders, and inflammatory diseases. Cannabinoids imitate naturally occurring compounds and interact with two specific types of receptors: CB1 and CB2, located in the nervous system and immune system, respectively. Shown here is an isocratic separation of fourteen cannabinoids in less than twelve minutes on an Ascentis® Express C18 column. Cerilliant cannabinoid CRMs provide reliable identification and quantification. These standards are used in testing methods by GC/MS, LC/MS, or HPLC for applications in clinical toxicology, testing of cannabis potency or impurity profiling by growers, pharmaceutical research, forensic analysis, and urine drug testing.

法的情報

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany